Hostname: page-component-586b7cd67f-l7hp2 Total loading time: 0 Render date: 2024-11-24T06:33:11.589Z Has data issue: false hasContentIssue false
  • English
  • Français

Alzheimer's Disease

Published online by Cambridge University Press:  07 November 2014

Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
In Session
Information
CNS Spectrums , Volume 14 , Issue 5 , May 2009 , pp. 248 - 251
Copyright
Copyright © Cambridge University Press 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Loveman, E, Green, C, Kirby, J, et al.The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease. Health Technol Assess. 2006;10(1):iii–iv, ix–xi, 1–160.CrossRefGoogle ScholarPubMed
2.Qin, W, Chachich, M, Lane, M, et al.Calorie restriction attenuates Alzheimer's disease type brain amyloidosis in Squirrel monkeys (Saimiri sciureus). J Alzheimers Dis. 2006;10:417–422.CrossRefGoogle ScholarPubMed
3.Greenberg, SM, Rosand, J, Schneider, AT, et al.A phase 2 study of tramiprosate for cerebral amyloid angiopathy. Alzheimer Dis Assoc Disord. 2006;20:269–274.CrossRefGoogle ScholarPubMed
4.Small, SA, Gandy, S. Sorting through the cell biology of Alzheimer's disease: intracellular pathways to pathogenesis. Neuron. 2006;52:15–31.CrossRefGoogle ScholarPubMed
5.Martins, IJ, Hone, E, Foster, JK, et al.Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease. Mol Psychiatry. 2006;11:721–736.CrossRefGoogle ScholarPubMed
6.Gandy, S, Heppner, FL. Breaking up (amyloid) is hard to do. PLoS Med. 2005;2:e417.CrossRefGoogle ScholarPubMed
7.Balakrishnan, K, Verdile, G, Mehta, PD, et al.Plasma Abeta42 correlates positively with increased body fat in healthy individuals. J Alzheimers Dis. 2005;8:269–282.CrossRefGoogle ScholarPubMed
8.Lautenschlager, NT, Wu, JS, Laws, SM, et al.Neurological soft signs are associated with APOE genotype, age and cognitive performance. J Alzheimers Dis. 2005;7:325–330.CrossRefGoogle ScholarPubMed
9.Gandy, S, Heppner, FL. Alzheimer's amyloid immunotherapy: quo vadis? Lancet Neurol. 2005;4:452–453.CrossRefGoogle ScholarPubMed
10.Gandy, S. The role of cerebral amyloid beta accumulation in common forms of Alzheimer disease. J Clin Invest. 2005;115:1121–1129.Google ScholarPubMed
11.Walker, LC, Ibegbu, CC, Todd, CW, et al.Emerging prospects for the disease-modifying treatment of Alzheimer's disease. Biochem Pharmacol. 2005;69:1001–1008.CrossRefGoogle ScholarPubMed
12.Gandy, S, Walker, L. Toward modeling hemorrhagic and encephalitic complications of Alzheimer amyloid-beta vaccination in nonhuman primates. Curr Opin Immunol. 2004;16:607–615.CrossRefGoogle ScholarPubMed
13.Heppner, FL, Gandy, S, McLaurin, J. Current concepts and future prospects for Alzheimer disease vaccines. Alzheimer Dis Assoc Disord. 2004;18:38–43.CrossRefGoogle ScholarPubMed
14.Gandy, S. Cerebral Abeta amyloidosis and postmenopausal hormone deficiency: roles in the genesis of Alzheimer's disease. Hum Pathol. 2004;35:271–274.CrossRefGoogle ScholarPubMed
15.Gandy, S, DeMattos, RB, Lemere, CA, et al.Alzheimer's Abeta vaccination of rhesus monkeys (Macaca mulatta). Mech Ageing Dev. 2004;125:149–151.CrossRefGoogle ScholarPubMed